Close

Precigen Inc. (PGEN) Reports First Patient Dosing with UltraCAR-T Cells in Ongoing PRGN-3005 & PRGN-3006 Phase 1 Clinical Trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


Go back to Precigen Inc. (PGEN) Reports First Patient Dosing with UltraCAR-T Cells in Ongoing PRGN-3005 & PRGN-3006 Phase 1 Clinical Trials
(NASDAQ: PGEN) Delayed: 1.40 +0.02 (1.45%)
Previous Close $1.38    52 Week High $ 
Open $1.40    52 Week Low $ 
Day High $1.45    P/E N/A 
Day Low $1.39    EPS $ 
Volume 507,017